Radioiodine Therapy of Thyroid Cancer
Differentiated thyroid cancers are typically iodine-avid and can be effectively treated with radioiodine. In most patients, radioactive iodine therapy (RAI) is done for ablation of residual tissue or with adjuvant intent in case of suspected persistent disease after surgery. Patient with advanced or metastatic disease may also benefit from RAI. In this chapter, we will discuss the current role of 131I-iodide therapy, including patient’s selection and preparation, and the importance of individual response to therapy to guide subsequent patient management.
KeywordsRadioiodine therapy Thyroid cancer Risk stratification
- 1.Curado MP, Edwards B, Shin HR, et al. Cancer incidence in five continents. vol 9. IARC Scientific Publications No. 160. Lyon: IARC; 2007.Google Scholar
- 6.Haugen BR, Alexander EK, Bible KC, et al. 2015 American thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid. 2016;26(1):1–133.CrossRefPubMedPubMedCentralGoogle Scholar
- 7.SEER Stat Fact Sheets: Thyroid Cancer. Surveillance, Epidemiology, and End Results Program. http://seer.cancer.gov/statfacts/html/thyro.html. Accessed 12 Mar 2017.
- 11.Tuttle RM, Tala H, Shah J, et al. Estimating risk of recurrence in differentiated thyroid cancer after total thyroidectomy and radioactive iodine remnant ablation: using response to therapy variables to modify the initial risk estimates predicted by the new American Thyroid Association staging system. Thyroid. 2010;20:1341–9.CrossRefPubMedPubMedCentralGoogle Scholar
- 13.American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer, Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, Mazzaferri EL, Mclver B, Pacini F, Schlumberger M, Sherman SI, Steward DL, Tuttle RM. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2009;19(11):1167–214.CrossRefGoogle Scholar
- 17.Pacini F, Ladenson PW, Schlumberger M, et al. Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin in differentiated thyroid carcinoma: results of an international, randomized, controlled study. J Clin Endocrinol Metab. 2006;91:926–32.CrossRefPubMedGoogle Scholar
- 18.Elisei R, Schlumberger M, Driedger A, et al. Follow-up of low-risk differentiated thyroid cancer patients who underwent radioiodine ablation of postsurgical thyroid remnants after either recombinant human thyrotropin or thyroid hormone withdrawal. J Clin Endocrinol Metab. 2009;94(11):4171–9.CrossRefPubMedGoogle Scholar
- 28.Baudin E, Schlumberger M. Metastasis of differentiated cancers of the thyroid. Ann Endocrinol (Paris). 1997;58:326–9.Google Scholar